Disease-free survival as surrogate for overall survival in esophageal cancer: An individual patient data meta-analysis of neoadjuvant chemotherapy and chemoradiotherapy.

Date publication

février 2025

Journal

European journal of cancer (Oxford, England : 1990)

Auteurs

Membres identifiés du Cancéropôle Est :
Dr VERNEREY Dewi

Tous les auteurs :
Cabrit N, Cheugoua-Zanetsie M, Tierney J, Thirion P, Nankivell M, Winter K, Yang H, Wijnhoven B, Vernerey D, Smithers BM, Piessen G, Nilsson M, Boonstra J, Ychou M, Law S, Cunningham D, Vathaire F, Stahl M, Urba S, Valmasoni M, Williaume D, Thomas J, Lordick F, Tepper J, Gebski V, Burmeister B, Paoletti X, Sandick JV, Fu J, Pignon JP, Ducreux M, Faron M, Michiels S,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/39938127

Résumé

The use of surrogate endpoints may expedite the reporting of study outcomes of clinical trials. The validity of disease-free survival (DFS) as a surrogate for overall survival (OS) in the neoadjuvant treatment of esophageal (E) or gastroesophageal junctional (GEJ) carcinomas remains uncertain.

Mots clés

Chemotherapy, Esophageal cancer, Gastroesophageal junction, Individual patient data network meta-analysis, Preoperative, Radiotherapy, Surrogate endpoint

Référence

Eur J Cancer. 2025 02 7;218:115292